• BMS-777607 Workflows for MET Signaling Research

  2026-09-16

  BMS-777607 supports controlled MET-family pathway studies across cancer metastasis models and exploratory megakaryocyte maturation assays. This guide separates validated product evidence from practical screening recommendations so researchers can optimize target engagement, platelet differentiation, and reproducible controls.

• Mubritinib–HSA Recognition: Methods and Implications

  2026-09-16

  This study combines fluorescence spectroscopy, biochemical testing, and molecular docking to define how mubritinib recognizes human serum albumin. Its evidence for static quenching, site I binding, structural perturbation, and competitive inhibition of albumin esterase-like activity provides a mechanistic basis for interpreting distribution and protein-mediated effects of this mitochondrial electron transport chain inhibitor.

• JZL184: Monoacylglycerol Lipase Inhibitor Workflows

  2026-09-15

  JZL184 provides a practical way to elevate endogenous 2-arachidonoylglycerol while probing CB1-dependent synaptic, astrocytic, pain, and behavioral pathways. This guide translates MAGL inhibition into cell, slice, and traumatic brain injury workflows, with formulation controls and troubleshooting steps that help separate mechanism from CB1-related behavioral confounds.

• Dihydrotestosterone DHT: Practical Research Workflows

  2026-09-15

  Dihydrotestosterone enables controlled interrogation of androgen receptor signaling, EGFR/ERBB2 crosstalk, and muscle-protection phenotypes. This workflow-centered guide connects cell-based dose response, ALS-model considerations, and a carefully bounded comparison with nutrient-restricted SSC meiosis research.

• TDG, ATF4, and mTORC1 in Cell Fate

  2026-09-14

  This preprint identifies TDG as an active coordinator of ATF4-dependent transcription during retinoic acid-induced neural fate acquisition, linking promoter chromatin organization to mTORC1 activity. Its multi-omic design provides a framework for studying how DNA demethylation machinery, stress-responsive transcription, and metabolic signaling jointly stabilize differentiated cell states.

• RNA Pol II Inhibition and Apoptotic Signaling

  2026-09-14

  Harper et al. show that RNA Pol II inhibition kills cells through an active apoptotic response triggered by loss of hypophosphorylated RNA Pol IIA, rather than through transcriptional collapse alone. The findings define the Pol II degradation-dependent apoptotic response and provide a framework for interpreting transcription-targeting drugs and designing complementary cell-death experiments.

• GRK Control of M1 Receptor Biased Signaling

  2026-09-13

  The reference study uses BRET-based interaction profiling to show that GRK subtype behavior helps determine whether M1 muscarinic receptor signaling favors G proteins or β-arrestin 2. Its analysis positions BQCA as a mechanistically informative M1 allosteric modulator and provides a framework for studying acetylcholine receptor signaling relevant to cognitive function modulation and Alzheimer’s disease research.

• BMS-777607: A Decision Framework for MET Studies

  2026-09-12

  BMS-777607 is a selective c-Met inhibitor for separating MET signaling pathway inhibition from small-molecule control of megakaryocyte assays. This evidence-aware guide connects cancer metastasis models with hiPSC-derived platelet research while clarifying validated findings, practical parameters, and experimental limits.

• 25-Hydroxycholesterol Reprograms TAM Immunity

  2026-09-11

  Xiao et al. identify the CH25H–25-hydroxycholesterol axis as an immunometabolic checkpoint that links lysosomal lipid sensing to AMPK–STAT6 activation in tumor-associated macrophages. Their findings show that targeting CH25H can improve T-cell surveillance and enhance anti-PD-1 efficacy, while providing a framework for separating macrophage cholesterol signaling from parallel tumor lactate-transport mechanisms.

• AR Heterogeneity Shapes Prostate Cancer Drug Response

  2026-09-11

  Li et al. showed that androgen receptor heterogeneity is functionally linked to distinct castration and enzalutamide responses in advanced prostate cancer. By combining patient specimens, xenografts, genome-edited cell models, transcriptomics, and combination treatment experiments, the study identified BCL-2 as a candidate vulnerability in AR-low or AR-negative disease.

• Mifepristone (RU486): Applied Research Workflows

  2026-09-10

  Mifepristone (RU486) enables controlled progesterone receptor perturbation across oncology, reproductive biology, and hormone-response assays. This practical guide covers formulation, dose-response design, orthogonal readouts, and troubleshooting for reproducible research use.

• CD36 Lipid Signaling Drives Immune Escape in AML

  2026-09-10

  Guo et al. identify a non-canonical CD36 lipid-sensing program that enables AML cells to suppress T-cell activity and resist decitabine-associated treatment effects. The study separates this immune function from conventional lipid oxidation and shows that statin-mediated disruption of CD36 signaling can improve decitabine efficacy in preclinical models.

• BMX-IN-1: From Target Engagement to Host Defense

  2026-09-09

  Explore how the BMX kinase inhibitor BMX-IN-1 can connect covalent target engagement with cancer phenotypes and host-pathogen biology. This article emphasizes causal assay design, lysosomal acidification, and the practical limits of translating BMX inhibition across disease models.

• Ibuprofen: Assay Workflows for Cancer Research

  2026-09-09

  Build more interpretable Ibuprofen experiments by separating COX pathway activity, cytotoxicity, apoptosis, and cell-cycle effects. This workflow combines practical dosing controls with protein-binding considerations inspired by a mechanistic reference study.

• TBST: From Assay Clarity to Translational Confidence

  2026-09-08

  TBST is more than a routine wash solution: its detergent-buffer chemistry can influence background, antibody accessibility, and the confidence of translational evidence. This article connects TBST workflow design with the orthogonal validation strategy used to investigate uPAR–uPA inhibition in breast cancer metastasis.

3643 records 1/243 page Next 12345 下5页 Last page